Share Email Print

Proceedings Paper • new

fluorescence-guided surgery with panitumumab-IRDye800 and cetuximab-IRDye800 in glioblastoma patients (Conference Presentation)
Author(s): Quan Zhou; Sarah E. Miller; Nynke S. van den Berg; Guolan Lu; Hannes Vogel; Romain Cayrol; Nicholas J. Oberhelman; Stefania U. Chirita; Stan van Keulen; Gerald A. Grant; Gordon H. Li; Eben L. Rosenthal
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Introduction: Glioblastoma (GBM) is the most common and devastating primary brain tumor. The recurrence rate remains high with a median survival of 15 months. GBM’s infiltrative nature results in ill-defined margins that makes maximal tumor resection with minimal morbidity a challenge. Epidermal growth factor receptor (EGFR) is the most frequently amplified gene in GBM (35-45% of tumors) and is associated with overexpression in about 40-98% of cases, a characteristic of more aggressive phenotypes. We hypothesize that fluorescence labeled anti-EGFR monoclonal antibodies (mAb), panitumumab-IRDye800 (pan800) and cetuximab-IRDye800 (cet800), could be leveraged to enhance tumor contrast during surgical resection and improve patient outcome. Methods: 50mg fluorescently labeled corresponding study drugs, pan800 and cet800 respectively, were administered 1-2 days in glioblastoma patients with contrast enhancing (CE) tumors prior to surgery following 100 mg loading dose of unlabeled cetuximab or panitumumab. Near-infrared fluorescence imaging of tumor and histologically negative peri-tumoral tissue was performed intraoperatively and ex vivo. Fluorescence was measured as mean fluorescence intensity (MFI), and tumor-to-background ratios (TBRs) were calculated by comparing MFIs of tumor and histologically uninvolved tissue. Results: Despite heterogeneous drug uptake across all resected brain tissues, mean fluorescence intensity (MFI) correlated strongly (R^2=0.97) with tumor volume among histologically confirmed tumor tissues. The smallest detectable tumor size in a closed-field setting was 4.2 x 2.7 mm^2 (8.2 mg) for pan800 and 8.5 x 6.6 mm^2 (70mg) for cet800. Tumor tissues from pan800 infusion had significantly higher mean TBR (8.1 ± 4.6) than cet800 infused ones in intraoperative imaging (3.3 ± 2.7; P = 0.004). NIR fluorescence from both test drugs provided high contrast to identify as few as a cluster of (5 ± 1) tumor cells in macroscopic imaging of whole sections of paraffin embedded tissues. Sensitivity and specificity of MFI for viable tumor detection was calculated and fluorescence was found to be highly sensitive (64.4% for pan800, 73.0% for cet800) and specific (98.0% for pan800, 66.3% for cet800) for viable tumor tissue while normal peri-tumoral tissue showed minimal fluorescence. No related grade-2 adverse events were observed 30 days beyond the infusion of either study drugs. Conclusion: EGFR antibody based imaging for contrast-enhanced glioblastomas proved safe in human patients and specific intratumoral delivery of NIR fluorescence provided high optical contrast and resolution for intraoperative image-guided resection. Fully humanized panitumumab-IRDye800 demonstrated superior detection sensitivity and tumor specificity over the chimeric cetuximab-IRDye800.

Paper Details

Date Published: 4 March 2019
Proc. SPIE 10862, Molecular-Guided Surgery: Molecules, Devices, and Applications V, 108620Y (4 March 2019); doi: 10.1117/12.2510366
Show Author Affiliations
Quan Zhou, Stanford Univ. (United States)
Stanford Univ. School of Medicine (United States)
Sarah E. Miller, Stanford Univ. (United States)
Nynke S. van den Berg, Stanford Univ. (United States)
Guolan Lu, Stanford Univ. (United States)
Hannes Vogel, Stanford Univ. School of Medicine (United States)
Romain Cayrol, Stanford Univ. School of Medicine (United States)
Nicholas J. Oberhelman, Stanford Univ. (United States)
Stefania U. Chirita, Stanford Univ. (United States)
Stan van Keulen, Stanford Univ. (United States)
Gerald A. Grant, Stanford Univ. School of Medicine (United States)
Gordon H. Li, Stanford Univ. School of Medicine (United States)
Eben L. Rosenthal, Stanford Univ. (United States)
Stanford Cancer Institute (United States)

Published in SPIE Proceedings Vol. 10862:
Molecular-Guided Surgery: Molecules, Devices, and Applications V
Brian W. Pogue; Sylvain Gioux, Editor(s)

© SPIE. Terms of Use
Back to Top